phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
Published 4 years ago • 693 plays • Length 3:44
Download video MP4
Download video MP3
Similar videos
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
8:12
evaluating teclistamab in relapsed and/or refractory multiple myeloma
-
4:28
first-in-human study of tnb-383b, a bcma x cd3 bispecific t-cell redirecting antibody, in pts w/rrmm
-
7:25
updated data: phase 1/2 majestec-1 study evaluating teclistamab, a bcma x cd3 bispecific antibody
-
6:36
updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory mm
-
7:26
regn5458, a bcmaxcd3 bispecific monoclonal antibody, in a phase 1/2 1st-in-human study in rrmm pts
-
18:32
updates in multiple myeloma from asco 2020
-
11:22
updated efficacy/safety results of majestec-1 (teclistamab) at asco 2022
-
4:26
what are bispecific antibodies?
-
2:21
180 updated phase 1 results of teclistamab, a bcma x cd3 bispecific antibody
-
5:06
durability of responses with biweekly dosing of teclistamab in pts with relapsed/refractory myeloma
-
4:56
updates on phase 1b trimm-2 study results of teclistamab daratumumab presented at eha 2022
-
8:43
results from monumental-1: first-in-human study of talquetamab in pts with rr multiple myeloma
-
5:38
teclistamab for r/r myeloma
-
9:14
efficacy and safety of elranatamab in pts with relapsed/refractory multiple myeloma: magnetismm-3
-
12:17
updated iv and sc results from a phase i dose escalation study of forimtamig with rrmm patients
Clip.africa.com - Privacy-policy